Pfizer posted fourth-quarter earnings that satisfied investors and analysts. But its guidance for 2016? Not so much.
Pfizer has quietly shuttered a Phase II Alzheimer's drug study, noting the termination in a pipeline update released today with its annual numbers for 2015. And shares of Axovant tumbled 16% on the news as it faces fresh questions about the implications of the failure on a similar drug it has pushed into a Phase III trial.
Allergan's $160 billion inversion merger with Pfizer and its attendant whacking of U.S. taxes has raised some hackles in Washington. Now, Allergan seems to be offering a bit of sugar to make the tax-avoiding medicine go down by talking about doubling employment at its flagship plant in Texas.
Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan's growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.
As it prepares to be subsumed in the $160 billion merger deal with Pfizer, Ireland's Allergan is not backing away from making deals. The company unveiled a three-way pact with AstraZeneca this morning to develop a new antibiotic with the help of a U.S. government agency.
A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.
Pfizer has had its hands full trying to protect its top-selling drug, pain and epilepsy med Lyrica, from generic competition in the U.K. Now it has a new distraction from the med, a recall in the U.S.
Pfizer owned TV ad spending for 2015 among pharma brands. It took 5 spots on the top 10 list for the year, including Nos. 1 and 2, according to iSpot.tv estimated spending tallied for FiercePharmaMarketing.
Pfizer's new cancer standout, Ibrance, has taken its first step toward joining the U.K.'s Early Access to Medicines program, winning the "promising innovative medicine" tag from the country's Medicines and Healthcare Regulatory Agency.
A Chinese ingredient maker who has produced ingredients for some of the big guns in pharma including Novartis, Sanofi and Pfizer is getting its products banned by the FDA.